These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 18487794)

  • 1. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
    Smart A; Martin P
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events.
    Ohashi W; Tanaka H
    J Med Syst; 2010 Aug; 34(4):701-7. PubMed ID: 20703925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental drug treatment cost in HIV-positive patients in industry-sponsored clinical trials.
    Perrín RS; López FJ
    Ann Pharmacother; 2008 Nov; 42(11):1586-91. PubMed ID: 18780807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
    Glasziou PP
    Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug costs: research and development costs: the great illusion.
    Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delays in new drug applications in Japan and industrial R&D strategies.
    Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics in Europe: barriers and opportunities.
    Gurwitz D; Zika E; Hopkins MM; Gaisser S; Ibarreta D
    Public Health Genomics; 2009; 12(3):134-41. PubMed ID: 19204415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
    Kock M; Thomsen MK
    Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing.
    Deverka PA; McLeod HL
    Clin Pharmacol Ther; 2008 Aug; 84(2):191-3. PubMed ID: 18679180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobilizing pharmacogenomic analyses during clinical trials in drug development.
    Bienfait KL; Shaw PM; Murthy G; Warner AW
    Pharmacogenomics; 2013 Jul; 14(10):1227-35. PubMed ID: 23859576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical drug trials in Germany--an assessment of current status from the viewpoint of industry].
    Baumbauer E
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():646-50. PubMed ID: 9101960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing clinical grant costs.
    Glass HE; Hollander K
    Contemp Clin Trials; 2009 May; 30(3):221-6. PubMed ID: 19470309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan.
    Ishiguro A; Yagi S; Uyama Y
    J Hum Genet; 2013 Jun; 58(6):313-6. PubMed ID: 23657427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The decision to conduct a head-to-head comparative trial: a game-theoretic analysis.
    Mansley EC; Elbasha EH; Teutsch SM; Berger ML
    Med Decis Making; 2007; 27(4):364-79. PubMed ID: 17761957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.